ClinicalTrials.gg
WithdrawnNCT06816017Updated Jun 16, 2025

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

A Phase 1 interventional study of Eciskafusp Alfa and BCG Medac Strain in Non-muscle Invasive Bladder Cancer, sponsored by Hoffmann-La Roche. Withdrawn at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-16.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Decision of the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Netherlands — 4 open to participants now, 6 under way, 2 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · Netherlands.

Enrollment
10th of 10
0 · median 205
Started
2025
with 2 others
Phase 1
2 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Hoffmann-La Roche

Among the 11 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Netherlands, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 9th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

4 of the 11 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

The study aims to establish the safety, tolerability, pharmacokinetics (PK), relevant biomarkers, pharmacodynamics (PD) and preliminary anti-tumor activity of the intravesical administration of eciskafusp alfa in combination with BCG in participants with BCG-unresponsive high-risk NMIBC.

The study plans a similar evaluation of eciskafusp alfa in monotherapy following a positive interim analysis of the combination therapy.

03

Conditions studied

  • Non-muscle Invasive Bladder Cancer

Keywords

  • BCG-unresponsive Non-muscle Invasive Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed high risk non muscle invasive transitional cell carcinoma classified according to World Health Organization (WHO) grading system
  • Absence of resectable disease after transurethral resection of bladder tumor (TURBT) procedures
  • The most recent cystoscopy/TURBT must have been performed within 12 weeks and up to 14 days of the first dose of study treatment
  • Presence of BCG-unresponsive disease defined as persistent or recurrent carcinoma in situ [CIS] (± recurrent Ta/T1 disease) within 12 months of receiving adequate BCG therapy
  • The participant is considered ineligible for radical cystectomy or has elected not to undergo the procedure.
  • Negative surface antigen (HBsAg) test at screening
  • Positive hepatitis B surface antibody (HBsAb) test at screening
  • Negative virus (HCV) antibody test at screening

Exclusion criteria

Exclusion Criteria:

  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
  • Active infections (both systemic and local urinary)
  • Congenital or acquired immune deficiencies resulting in
  • Known (HIV) infection
  • History of radiotherapy of the bladder
  • History of perforation of the bladder
  • Major surgery or significant traumatic injury within 28 days prior to first administration of study treatment or anticipation of the need for major surgery during treatment
  • Participants currently receiving or commercial anti-cancer agents or anti-cancer therapies other than BCG, and supportive care therapies for active disease
  • Any intervening intravesical immunotherapy or chemotherapy from the time of the most recent cytoscopy/TURBT to the start of study treatment
  • Systemic immune-modulating and systemic immunosuppressive agents/medication
  • Administration of a live, attenuated vaccine within 28 days prior to first administration of study treatment
  • Recurrence of BCG unresponsive CIS > 12 months after last BCG instillation
  • Concurrent second
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase I: Dose Escalation

    Participants will receive multiple ascending doses of eciskafusp alfa in combination with a fixed dose of BCG administered as an intravesicular instillation up to a maximum of 25 months or until detection of high-risk disease or disease progression, toxicity, or withdrawal from study treatment for other reasons, whichever occurs first.

    Drug: Eciskafusp Alfa · Drug: BCG Medac Strain

  • Experimental
    Phase II: Dose Extension (Cohort A)

    Participants will receive eciskafusp alfa at the maximum tolerated dose (MTD) and/or the recommended dose for extension (RDE), as determined in Phase 1, in combination with a fixed dose of BCG administered as an intravesical instillation up to a maximum of 25 months or until detection of high-risk disease or disease progression, toxicity, or withdrawal from study treatment for other reasons, whichever occurs first.

    Drug: Eciskafusp Alfa · Drug: BCG Medac Strain

  • Experimental
    Phase II: Dose Extension (Cohort B)

    Participants will receive eciskafusp alfa as monotherapy at the MTD or RDE determined in Phase 1, administered as an intravesical instillation up to a maximum of 25 months or until detection of high-risk disease or disease progression, toxicity, or withdrawal from study treatment for other reasons, whichever occurs first.

    Drug: Eciskafusp Alfa

Interventions

  • DrugEciskafusp Alfa

    Participants will receive eciskafusp alfa via intravesical instillation.

    Also known as: RO7284755

  • DrugBCG Medac Strain

    Participants will receive BCG via intravesical instillation.

06

What researchers measure

Primary outcomes

  1. Phase I: Number of Participants With Adverse Events (AEs)

    Time frame: From Baseline (Day 1) up to 28 days after final dose of study treatment (up to Month 26)

  2. Phase I: Number of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: From Day 1 up to Day 14

  3. Phase I: Recommended Dose for Extension (RDE) of Eciskafusp Alfa in Combination With BCG

    Time frame: At Month 25

  4. Phase II (Cohort A): Complete Response Rate (CRR) at 12 Months

    Time frame: At Month 12

Secondary outcomes

  1. Phase I and Phase II: CRR at any Time

    Time frame: Up to Month 36

  2. Phase I and Phase II: CRR at 6, 18 and 24 Months

    Time frame: At Months 6, 18 and 24

  3. Phase I and Phase II (Cohort B): CRR at 12 Months

    Time frame: At Month 12

  4. Phase I and Phase II: Duration of Response (DOR)

    Time frame: Time from the first occurrence of a documented CR until the time of evidence that the participant no longer meets the definition for CR or death from any cause, whichever occurs first (up to Month 36)

  5. Phase I and Phase II: DOR Rate at Specific Timepoints

    Time frame: At Months 6, 12, 18, 24, 30 and 36

  6. Phase I and Phase II: Time to Worsening of NMIBC Grade or Stage, or Death

    Time frame: Time from the first dose of study treatment to the first occurrence of documented worsening of grade, stage or death from any cause, whichever occurs first (up to Month 36)

  7. Phase I and Phase II: Progression Free Survival (PFS) to Muscle Invasive or Metastatic Disease or Death

    Time frame: Time from the first dose of study treatment to the first occurrence of documented muscle-invasive or metastatic disease or death from any cause, whichever occurs first (up to Month 36)

  8. Phase I and II: Time to Cystectomy

    Time frame: Time from the first dose of study treatment to the first occurrence of documented cystectomy or death from any cause, whichever occurs first (up to Month 36)

  9. Phase II: Number of Participants With AEs

    Time frame: From Baseline (Day 1) up to 28 days after final dose of study treatment (up to Month 26)

  10. Phase I and Phase II: Number of Participants With Anti-drug Antibodies (ADAs) to Eciskafusp Alfa

    Time frame: Up to Month 36

  11. Phase II: Programmed Cell Death Ligand 1 (PD-L1) Expression in the Tumor Microenvironment (TME) Pre-treatment and During the Study

    PD-L1 expression may be assessed at other timepoints when on-treatment biopsies will be collected.

    Time frame: Predose (-12 weeks to -14 days or archival) and Postdose at Month 6

  12. Phase II: Number of Participants With Cluster of Differentiation 8+ (CD8+) T cell in TME

    Time frame: Predose (-12 weeks to -14 days or archival)

  13. Phase II: Baseline Urine Tumor Deoxyribonucleic Acid (DNA)

    Time frame: Baseline (Day 1 predose)

  14. Phase II: Amount of Urine Tumor DNA at Baseline and During the Study

    Time frame: Up to Month 25

07

Study locations

9 sites
  • Macquarie University Hospital
    Macquarie Park, New South Wales 2113, Australia
  • A.O.U di Verona Policlinico G.B. Rossi
    Verona, Veneto 37134, Italy
  • Hospital Umum Sarawak
    Kuching, Sarawak 93586, Malaysia
  • NKI/AvL
    Amsterdam, 1066 CX, Netherlands
  • UMC St Radboud
    Nijmegen, 6525 GA, Netherlands
  • Uniwersyteckie Centrum Kliniczne
    Gda?sk, 80-214, Poland
  • AIDPORT Sp. z o. o.
    Skórzewo, 60-185, Poland
  • Hospital Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Clinico Universitario Virgen de la Victoria
    Malaga, 29010, Spain
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Oct 2028, 40 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 10, 2025
StartEst.
Jun 15, 2025
Primary completionEst.
Oct 31, 2028
CompletionEst.
Oct 31, 2030
Last update
Jun 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06816017
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Jun 15, 2025 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Jun 16, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion